SequelSEC

Inhibitor Therapeutics, Inc. INTI

Pharmaceutical Preparations · CIK 0001042418 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2022-09-30
Operating income
-$263.05K
Fiscal year ended 2022-09-30
Free cash flow
Unavailable
Fiscal year ended 2022-09-30

Inhibitor Therapeutics, Inc. (INTI) reported revenue of $0 and net income of -$287.73K for the fiscal year ended 2022-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Inhibitor Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Inhibitor Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-09-30
Revenue$0
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$263.05K
Net income-$287.73K
Research & development$6.22K
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$256.82K
Selling & marketingUnavailable

Balance

Inhibitor Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-09-30
Cash & equivalents$53.06K
Total assets$63.12K
Current assets$63.12K
Total liabilities$4.09M
Current liabilities$1.09M
Total equity incl. NCI-$4.02M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$326.46K

Cash flow

Inhibitor Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-09-30
Operating cash flow-$180.23K
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$180.00K
Net change in cash-$229
Stock-based compensation$0
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Inhibitor Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-09-30
Free cash flowUnavailable
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio0.06x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open INTI in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.